ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2016

May 24, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2016-05-20

Reporting Person: Smith David V (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-05-20	Common Stock	M	2500	—	Acquired	9500	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-05-20	Restricted Stock Unit (RSU)	$	M	2500	Disposed		Common Stock (2500)	Direct

Footnotes

F1: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.

F2: RSUs convert into common stock on a one-for-one basis.

F3: Each RSU represents a contingent right to receive one share of the issuer's common stock.

F4: The RSUs expire 30 days from the date they vest.